Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink

Archives of Pediatrics and Adolescent Medicine

Volumn 165, Issue 8, 2011, Pages 749-755

  Glanz, Jason M ^a,b   Newcomer, Sophia R ^a   Hambidge, Simon J ^a,c   Daley, Matthew F ^a,d   Narwaney, Komal J ^a,b   Xu, Stan ^a   Lee, Grace M ^e,f   Baggs, James ^g   Klein, Nicola P ^h   Nordin, James D ⁱ   Naleway, Allison L ^h   Belongia, Edward A ^j   Weintraub, Eric S ^g  

^a KAISER PERMANENTE   (United States)

^b Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

^c DENVER HEALTH   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^j MARSHFIELD CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ALLERGIC REACTION; ARTICLE; CELLULITIS; CHILD; CLINICAL EVALUATION; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; EMERGENCY WARD; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HUMAN; HYPOTENSION; INCIDENCE; INFANT; INFLUENZA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RISK; SCREENING; SECONDARY ANALYSIS; SELF CONTROL; SKIN MANIFESTATION; UNITED STATES;

CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MANAGED CARE PROGRAMS; POISSON DISTRIBUTION; POPULATION SURVEILLANCE; RISK; SAFETY; UNITED STATES; VACCINES, INACTIVATED;

EID: 79961115919     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2011.112     Document Type: Article

References (27)

1. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA; Advisory Committee on Immunization Practices. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2006;55(RR-10):1-42.
2. Fiore AE, Shay DK, Broder K, et al Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60.
3. Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics. 1991;87(6):823-828.
4. Piedra PA, Glezen WP, Mbawuike I, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993;11(7):718-724. (Pubitemid 23190656)
5. American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345(21):1529-1536.
6. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23(3):189-197.
7. Goodman MJ, Nordin JD, Harper P, Defor T, Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age [published correction appears in Pediatrics. 2006;118(3):1324]. Pediatrics. 2006;117(5): e821-e826. http://pediatrics.aappublications.org/cgi/pmidlookup?view= long&pmid=16651286. Accessed May 6, 2011. (Pubitemid 46071347)
8. Skowronski DM, Jacobsen K, Daigneault J, et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics. 2006;117(6):1963-1971. (Pubitemid 46071240)
9. Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine. 2009;27(32):4278-4283.
10. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004; 158(11):1031-1036. (Pubitemid 39458490)
11. Hambidge SJ, Glanz JM, France EK, et al Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296(16):1990-1997. (Pubitemid 44631445)
12. Centers for Disease Control and Prevention National Immunization Program. Record of the Meeting of the Advisory Committee on Immunization Practices, October 26-27, 2005. Atlanta, GA: Centers for Disease Control and Prevention; 2005:43. 2005.
13. Chen RT, Glasser JW, Rhodes PH, et al The Vaccine Safety Datalink Team. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99(6):765-773. (Pubitemid 27231345)
14. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol. 2010;171(2):177-188.
15. McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System, 1990-2003. Pediatrics. 2005; 115(2):453-460. (Pubitemid 43193830)
16. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51(1):228-235.
17. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143(11):1165-1173. (Pubitemid 26158114)
18. Glanz JM, McClure DL, Xu S, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol. 2006;59(8):808-818. (Pubitemid 43996937)
19. Mullooly JP, Donahue JG, DeStefano F, Baggs J, Eriksen E; VSD Data Quality Working Group. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med. 2008;47(4):328-335.
20. Shui IM, Shi P, Dutta-Linn MM, et al Vaccine Safety Datalink Research Team. Predictive value of seizure ICD-9 codes for vaccine safety research. Vaccine. 2009; 27(39):5307-5312.
21. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA; Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002;51(RR-3):1-31.
22. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106(5):E62.
23. Ashkenazi S, Vertruyen A, Arístegui J, et al CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25(10):870-879. (Pubitemid 44510578)
24. Wassilak SGF, Roper MR, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Amsterdam, the Netherlands: Elsevier Inc; 2008:805-840.
25. Jackson LA, Starkovich P, Dunstan M, et al. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheriatetanus-acellular pertussis vaccination. Pediatrics. 2008;121(3):e646-e652.
26. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292(20):2478-2481. (Pubitemid 39552672)
27. Centers for Disease Control and Prevention (CDC). Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.MMWR Morb Mortal Wkly Rep. 2009;58(48):1351-1356.